National Trends In Spending On And Use Of Oral Oncologics, First Quarter 2006 Through Third Quarter 2011
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
National Trends In Spending On And Use Of Oral Oncologics, First Quarter 2006 Through Third Quarter 2011
Authors
Keywords
-
Journal
HEALTH AFFAIRS
Volume 33, Issue 10, Pages 1721-1727
Publisher
Health Affairs (Project Hope)
Online
2014-10-07
DOI
10.1377/hlthaff.2014.0001
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Sorafenib (SOR) in patients (pts) with imatinib (IM) and sunitinib (SU)-resistant (RES) gastrointestinal stromal tumors (GIST): Final results of a University of Chicago Phase II Consortium trial.
- (2017) H. L. Kindler et al. JOURNAL OF CLINICAL ONCOLOGY
- The Slowdown In Health Care Spending In 2009–11 Reflected Factors Other Than The Weak Economy And Thus May Persist
- (2013) Alexander J. Ryu et al. HEALTH AFFAIRS
- Prevalence of Off-Label Use and Spending in 2010 Among Patent-Protected Chemotherapies in a Population-Based Cohort of Medical Oncologists
- (2013) Rena M. Conti et al. JOURNAL OF CLINICAL ONCOLOGY
- Cost Sharing and Adherence to Tyrosine Kinase Inhibitors for Patients With Chronic Myeloid Leukemia
- (2013) Stacie B. Dusetzina et al. JOURNAL OF CLINICAL ONCOLOGY
- Out of Pocket, Out of Sight? An Unmeasured Component of the Burden of Cancer
- (2013) Matthew P. Banegas et al. JNCI-Journal of the National Cancer Institute
- Growth In US Health Spending Remained Slow In 2010; Health Share Of Gross Domestic Product Was Unchanged From 2009
- (2012) Anne B. Martin et al. HEALTH AFFAIRS
- Phase 2 study of nilotinib as third-line therapy for patients with gastrointestinal stromal tumor
- (2011) Akira Sawaki et al. CANCER
- Projections of the Cost of Cancer Care in the United States: 2010-2020
- (2011) A. B. Mariotto et al. JNCI-Journal of the National Cancer Institute
- Health-related quality of life in patients with metastatic renal cell carcinoma treated with sunitinib vs interferon-α in a phase III trial: final results and geographical analysis
- (2010) D Cella et al. BRITISH JOURNAL OF CANCER
- How Medicare’s Payment Cuts For Cancer Chemotherapy Drugs Changed Patterns Of Treatment
- (2010) Mireille Jacobson et al. HEALTH AFFAIRS
- An economic evaluation of the war on cancer
- (2010) Darius N. Lakdawalla et al. JOURNAL OF HEALTH ECONOMICS
- Patient-reported outcomes in a phase III, randomized study of sunitinib versus interferon-α as first-line systemic therapy for patients with metastatic renal cell carcinoma in a European population
- (2009) D. Castellano et al. ANNALS OF ONCOLOGY
- A phase 2 study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic clear cell renal cell cancer
- (2009) Robert J. Amato et al. CANCER
- Dasatinib in the Treatment of Chronic Myeloid Leukemia in Accelerated Phase After Imatinib Failure: The START A Trial
- (2009) Jane F. Apperley et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy and Safety of Pazopanib in Patients With Metastatic Renal Cell Carcinoma
- (2009) Thomas E. Hutson et al. JOURNAL OF CLINICAL ONCOLOGY
- Limits on Medicare's Ability to Control Rising Spending on Cancer Drugs
- (2009) Peter B. Bach NEW ENGLAND JOURNAL OF MEDICINE
- Prescription Drug Spending Trends In The United States: Looking Beyond The Turning Point
- (2008) Murray Aitken et al. HEALTH AFFAIRS
- Long-Term Results From a Randomized Phase II Trial of Standard- Versus Higher-Dose Imatinib Mesylate for Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing KIT
- (2008) Charles D. Blanke et al. JOURNAL OF CLINICAL ONCOLOGY
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started